Too often, biopharma sales compensation plans that do not have a fixed budget, such as goal or commission, end up paying or more or less than expected. In this blog post, we explore an invaluable tool called a budget risk analysis that helps companies anticipate how much their plan will pay out before implementation.

The various frameworks under which a commission-based sales compensation plan can be designed offer biopharma companies great flexibility in tailoring a plan to the unique needs of their particular sales force and product portfolio. In this blog post, we explore the three major commission frameworks and when you should use each.

Although the forced rank sales compensation plan is one of the most popular designs utilized for a biopharma product launch, the launch stage is actually the stage in which forced rank does the most harm. In this blog post, we explore why you should avoid forced rank sales compensation plans for a product launch.

In this third and final part of our series dedicated to biopharma payout curve design, we explore how to set the payout threshold and slope of your sales compensation payout curve to drive sales force motivation and sales while being fiscally responsible.

Let’s explore three common pitfalls in designing goal-based payout curves and how they can undermine a company’s budget.

Sales compensation corrections are often made after the plan period has ended in order to address unforeseen circumstances, but does this actually motivate?